This page shows the latest HR+/HER2- metastatic disease news and features for those working in and with pharma, biotech and healthcare.
Almost one in three cases of early-stage breast cancer eventually become metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%, Gilead reported. ... As patients with HR+/HER2- metastatic breast
Almost one in three cases of early-stage breast cancer eventually become metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%, Gilead reported. ... We look forward to discussing the results with
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...